Author:
Einsele H,Bamberg M,Budach W,Schmidberger H,Hess C F,Wörmann B,Meisner C,Straka C,Hebart H,Trümper L,Kröger N,Zander A R,Hegewisch-Becker S,Hossfeld D K,Schmidt H,Müller P,Schlimok G,Hertenstein B,Peest D,Metzner B,Frickhofen N,Kanz L,Bensinger W I
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference29 articles.
1. Boccadoro M, Pileri A . Diagnosis, prognosis, and standard treatment of multiple myeloma. Clin Haematol Oncol N Am 1997; 11: 111–131.
2. Barlogie B . Plasma cell myeloma. In: Kipps T (ed.). Haematology. William's Haematology, 5th edn. McGraw-Hill: Baltimore, MD, 1995, pp 1109–1130.
3. Boccadoro M, Marmont F, Tribalto M et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991; 9: 444–448.
4. McElwain TJ, Powles RJ . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.
5. Fefer A, Cheever MA, Greenberg PD . Identical-twin (syngeneic) marrow transplantation for haematologic cancers. J Natl Cancer Inst 1986; 76: 1269–1273.